For the quarter ending 2026-03-31, ESPR made $80,104K in revenue. -$25,196K in net income. Net profit margin of -31.45%.
| Income Statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Total revenues | 80,104 | 151,557* | 87,309 | - |
| Cost of goods sold | 34,573 | 19,984* | 41,289 | - |
| Research and development | 8,988 | 7,820* | 14,131 | - |
| Selling, general and administrative | 43,124 | 38,521* | 41,848 | - |
| Total operating expenses | 86,685 | 66,324* | 97,268 | - |
| Loss from operations | -6,581 | 85,233 | -9,959 | 7,095 |
| Interest expense | 19,798 | 22,636 | 22,051 | 20,486 |
| Loss on extinguishment of debt and exchange transaction | - | -1,381 | 0 | 0 |
| Other income, net | 1,183 | 1,075 | 677 | 666 |
| Loss before income taxes | - | 62,291* | - | - |
| Provision for taxes on income | - | 460* | - | - |
| Net gain | -25,196 | 61,831 | -31,333 | -12,725 |
| Unrealized gain on investments | - | 0 | - | - |
| Comprehensive gain | -25,196 | 61,831 | -31,333 | -12,725 |
| Basic EPS | -0.1 | 0.261 | -0.16 | -0.06 |
| Diluted EPS | -0.1 | 0.261 | -0.16 | -0.06 |
| Basic Average Shares | 251,353,086 | 237,049,997 | 200,736,136 | 197,546,239 |
| Diluted Average Shares | 251,353,086 | 237,049,997 | 200,736,136 | 197,546,239 |
Esperion Therapeutics, Inc. (ESPR)
Esperion Therapeutics, Inc. (ESPR)